Literature DB >> 11878510

Ig-binding receptors on human NK cells as effector and regulatory surface molecules.

A Sulica1, P Morel, D Metes, R B Herberman.   

Abstract

The receptors on human natural killer 9NK cells which can specifically bind the Fc portion of immunoglobulin molecules (Fc receptors) have been extensively studied. The best known and studied Fc receptor on human NK cells is FcgammaRIIIa. Interactions of NK cells with IgG antibodies via this receptor are well known to induce a signal transduction cascade and lead to antibody-dependent cell-mediated cytotoxicity (ADCC) as well as release of various cytokines. In addition, interactions with monomeric IgG and FcgammaRIIIa have been demonstrated, which result in negative regulation of NK activity and other immunomodulatory effects. Over the past several years, it has also become increasingly appreciated that human NK cells express a variety of other Fc receptors, including FcmuR, which also can mediate effector and immunoregulatory functions. Also, a novel form of FcgammaR has been demonstrated on human NK cells, termed FcgammaRIIc. Recent molecular studies have shown considerable polymorphism in the genes for FcgammaIIc and the functional consequences are being dissected. This appears to include cross-talk between FcgammaRIIIa and at least some forms of FcgammaRIIc, which may have important functional consequences.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11878510     DOI: 10.3109/08830180109054414

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  18 in total

1.  The Rickettsia conorii autotransporter protein Sca1 promotes adherence to nonphagocytic mammalian cells.

Authors:  Sean P Riley; Kenneth C Goh; Timothy M Hermanas; Marissa M Cardwell; Yvonne G Y Chan; Juan J Martinez
Journal:  Infect Immun       Date:  2010-02-22       Impact factor: 3.441

2.  Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis.

Authors:  Hiroyuki Hanai; Takayuki Iida; Masami Yamada; Yoshihiko Sato; Ken Takeuchi; Tatsuo Tanaka; Kenji Kondo; Masataka Kikuyama; Yasuhiko Maruyama; Yasushi Iwaoka; Akiko Nakamura; Kazuhisa Hirayama; Abby R Saniabadi; Fumitoshi Watanabe
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

3.  Leukocytapheresis: An "Out-of-Body" Experience in Inflammatory Bowel Disease.

Authors:  Seymour Katz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-12

Review 4.  An immunology primer for computational modelers.

Authors:  William F Hawse; Penelope A Morel
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-09-20       Impact factor: 2.745

5.  Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity.

Authors:  Jorge Schettini; Amritha Kidiyoor; Dahlia M Besmer; Teresa L Tinder; Lopamudra Das Roy; Joseph Lustgarten; Sandra J Gendler; Pinku Mukherjee
Journal:  Cancer Immunol Immunother       Date:  2012-04-28       Impact factor: 6.968

Review 6.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

7.  Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor.

Authors:  Curtis H Kugel; Edward J Hartsough; Michael A Davies; Yulius Y Setiady; Andrew E Aplin
Journal:  Cancer Res       Date:  2014-07-17       Impact factor: 12.701

8.  Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.

Authors:  Liat Binyamin; R Katherine Alpaugh; Tracey L Hughes; Charles T Lutz; Kerry S Campbell; Louis M Weiner
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

9.  Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model.

Authors:  Bart G Jones; Robert E Sealy; Sherri L Surman; Allen Portner; Charles J Russell; Karen S Slobod; Philip R Dormitzer; John DeVincenzo; Julia L Hurwitz
Journal:  Vaccine       Date:  2014-04-14       Impact factor: 3.641

10.  Targeting the Late Stage of HIV-1 Entry for Antibody-Dependent Cellular Cytotoxicity: Structural Basis for Env Epitopes in the C11 Region.

Authors:  William D Tolbert; Neelakshi Gohain; Nirmin Alsahafi; Verna Van; Chiara Orlandi; Shilei Ding; Loïc Martin; Andrés Finzi; George K Lewis; Krishanu Ray; Marzena Pazgier
Journal:  Structure       Date:  2017-10-19       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.